NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Allogene Therapeutics
Ossium Health, Inc.
Fate Therapeutics
Celyad Oncology SA